Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5798571 | 0.73 | KCNH2 (0.35) | — | |
| Hydrochloric Acid SCHEMBL4067892 | 0.73 | KCNH2 (0.35) | — | |
| SCHEMBL10078632 | 0.72 | HTR2C (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3MAP4K1 | |
| SCHEMBL1224035 | 0.72 | CYP2C19 (0.43) | — | |
| SCHEMBL5366850 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5034124 | 0.72 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL899503 | 0.72 | BMPR1B (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7690304 | 0.71 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7690443 | 0.71 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1224675 | 0.71 | MAP4K1 (0.41) | NTRK1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | CHRNB2 4793/4885CHRNA4 4627/4885CHRNB4 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.